Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Venkatesh Pilla-Reddy

Showing results (21-30 of 57) with videos related to

Pageof 6
Sort By:
Drug Metabolism Letters|March 1, 2012
Preclinical metabolism and pharmacokinetics of SB1317 (TG02), a potent CDK/JAK2/FLT3 inhibitorMohammed Khalid Pasha, Ramesh Jayaraman, Venkatesh Pilla Reddy, et al.
Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy|July 31, 2023
Safety, tolerability, and pharmacokinetics of half-life extended SARS-CoV-2-neutralizing monoclonal antibodies AZD7442 (tixagevimab/cilgavimab) in healthy Japanese adultsHiroshi Okada, Kensuke Ishikawa, Yohji Itoh, et al.
British Journal of Clinical Pharmacology|November 23, 2020
Pharmacokinetics under the COVID-19 stormVenkatesh Pilla Reddy, Eman El-Khateeb, Heeseung Jo, et al.
Cancer Chemotherapy and Pharmacology|June 3, 2021
Mechanistic physiology-based pharmacokinetic modeling to elucidate vincristine-induced peripheral neuropathy following treatment with novel kinase inhibitorsVenkatesh Pilla Reddy, Adrian J Fretland, Diansong Zhou, et al.
Clinical Pharmacokinetics|June 10, 2011
Structural models describing placebo treatment effects in schizophrenia and other neuropsychiatric disordersVenkatesh Pilla Reddy, Magdalena Kozielska, Martin Johnson, et al.
Schizophrenia Research|February 26, 2013
Sensitivity of individual items of the Positive and Negative Syndrome Scale (PANSS) and items subgroups to differentiate between placebo and drug treatment in schizophreniaMagdalena Kozielska, Venkatesh Pilla Reddy, Martin Johnson, et al.
Communications Biology|August 25, 2021
Tumour-on-chip microfluidic platform for assessment of drug pharmacokinetics and treatment responseTudor Petreus, Elaine Cadogan, Gareth Hughes, et al.
Pharmaceutical Research|June 8, 2011
Mechanism-based pharmacokinetic-pharmacodynamic modeling of the dopamine D2 receptor occupancy of olanzapine in ratsMartin Johnson, Magdalena Kozielska, Venkatesh Pilla Reddy, et al.
Pharmaceutical Research|March 23, 2012
Pharmacokinetic-pharmacodynamic modeling of the D₂ and 5-HT (2A) receptor occupancy of risperidone and paliperidone in ratsMagdalena Kozielska, Martin Johnson, Venkatesh Pilla Reddy, et al.
Pharmaceutical Research|March 12, 2016
Erratum to: Translational Modeling in Schizophrenia: Predicting Human Dopamine D₂ Receptor OccupancyMartin Johnson, Magdalena Kozielska, Venkatesh Pilla Reddy, et al.
Pageof 6

Showing results (21-30 of 57) with videos related to

Sort By:
Pageof 6
Drug Metabolism Letters|March 1, 2012
Preclinical metabolism and pharmacokinetics of SB1317 (TG02), a potent CDK/JAK2/FLT3 inhibitorMohammed Khalid Pasha, Ramesh Jayaraman, Venkatesh Pilla Reddy, et al.
Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy|July 31, 2023
Safety, tolerability, and pharmacokinetics of half-life extended SARS-CoV-2-neutralizing monoclonal antibodies AZD7442 (tixagevimab/cilgavimab) in healthy Japanese adultsHiroshi Okada, Kensuke Ishikawa, Yohji Itoh, et al.
British Journal of Clinical Pharmacology|November 23, 2020
Pharmacokinetics under the COVID-19 stormVenkatesh Pilla Reddy, Eman El-Khateeb, Heeseung Jo, et al.
Cancer Chemotherapy and Pharmacology|June 3, 2021
Mechanistic physiology-based pharmacokinetic modeling to elucidate vincristine-induced peripheral neuropathy following treatment with novel kinase inhibitorsVenkatesh Pilla Reddy, Adrian J Fretland, Diansong Zhou, et al.
Clinical Pharmacokinetics|June 10, 2011
Structural models describing placebo treatment effects in schizophrenia and other neuropsychiatric disordersVenkatesh Pilla Reddy, Magdalena Kozielska, Martin Johnson, et al.
Schizophrenia Research|February 26, 2013
Sensitivity of individual items of the Positive and Negative Syndrome Scale (PANSS) and items subgroups to differentiate between placebo and drug treatment in schizophreniaMagdalena Kozielska, Venkatesh Pilla Reddy, Martin Johnson, et al.
Communications Biology|August 25, 2021
Tumour-on-chip microfluidic platform for assessment of drug pharmacokinetics and treatment responseTudor Petreus, Elaine Cadogan, Gareth Hughes, et al.
Pharmaceutical Research|June 8, 2011
Mechanism-based pharmacokinetic-pharmacodynamic modeling of the dopamine D2 receptor occupancy of olanzapine in ratsMartin Johnson, Magdalena Kozielska, Venkatesh Pilla Reddy, et al.
Pharmaceutical Research|March 23, 2012
Pharmacokinetic-pharmacodynamic modeling of the D₂ and 5-HT (2A) receptor occupancy of risperidone and paliperidone in ratsMagdalena Kozielska, Martin Johnson, Venkatesh Pilla Reddy, et al.
Pharmaceutical Research|March 12, 2016
Erratum to: Translational Modeling in Schizophrenia: Predicting Human Dopamine D₂ Receptor OccupancyMartin Johnson, Magdalena Kozielska, Venkatesh Pilla Reddy, et al.
Pageof 6